# Profound Hypoglycemia and High Anion Gap Metabolic Acidosis in a Pediatric Leukemic Patient Receiving 6-Mercaptopurine

**Authors:** Molly O’Shea, Alexis Kuhn, Ana L. Creo, Mira Kohorst, Asmaa Ferdjallah

PMC · DOI: 10.3390/children11020160 · Children · 2024-01-26

## TL;DR

A 13-year-old leukemia patient on 6-mercaptopurine developed severe hypoglycemia and acidosis, highlighting the need for vigilance in recognizing rare but serious drug side effects.

## Contribution

This case adds nuance to the literature by showing hypoglycemia and acidosis in a well-appearing child on 6MP without traditional risk factors.

## Key findings

- The patient exhibited severe hypoglycemia and metabolic acidosis while on 6-mercaptopurine therapy.
- Symptoms of hypoglycemia may be masked by common chemotherapy side effects, leading to underdiagnosis.
- Allopurinol and morning dosing of 6MP may help prevent hypoglycemia.

## Abstract

A 13-year-old male undergoing maintenance chemotherapy with methotrexate and 6-mercaptopurine (6MP), for very high-risk B-cell acute lymphoblastic leukemia (ALL), presented with vomiting due to severe hypoglycemia with metabolic acidosis. While his laboratory values were concerning for a critically ill child, the patient was relatively well appearing. Hypoglycemia is a rare but serious side effect of 6MP with an unexpectedly variable presentation; therefore, a high index of suspicion is needed for its prompt detection and treatment. This patient also had severe metabolic acidosis, likely secondary to hypoglycemia, creating a serious clinical picture despite a well-appearing child. This example of incongruity between laboratory tests and clinical appearance adds nuance to the existing literature. Moreover, although 6MP-associated hypoglycemia is rare, it may be more prevalent than the literature suggests, as symptoms of hypoglycemia—nausea, vomiting, and somnolence—mirror common chemotherapy side effects. 6MP-induced hypoglycemia can be ameliorated with the addition of allopurinol to shunt metabolism in favor of the production of therapeutic metabolites over hepatotoxic metabolites. Additionally, a morning administration of 6MP and frequent snacks may also help to prevent hypoglycemia. Overall, this case adds to the literature of unusual reactions to 6MP including hypoglycemia in an older child without traditional risk factors.

## Linked entities

- **Chemicals:** 6-mercaptopurine (PubChem CID 667490), methotrexate (PubChem CID 4112), allopurinol (PubChem CID 135401907)
- **Diseases:** B-cell acute lymphoblastic leukemia (MONDO:0004947), hypoglycemia (MONDO:0004946), metabolic acidosis (MONDO:0000440)

## Full-text entities

- **Diseases:** Leukemic (MESH:D007938), Hypoglycemia (MESH:D007003), vomiting (MESH:D014839), Metabolic Acidosis (MESH:D000138), critically ill (MESH:D016638), nausea, vomiting (MESH:D020250), somnolence (MESH:D006970), B-cell acute lymphoblastic leukemia (MESH:D015456)
- **Chemicals:** methotrexate (MESH:D008727), 6-Mercaptopurine (MESH:D015122), allopurinol (MESH:D000493)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10886981/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10886981/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC10886981/full.md

---
Source: https://tomesphere.com/paper/PMC10886981